All In Biotech

Drug Trial Radar · NCT03714373

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Oct 1, 2018

Primary completion

Aug 17, 2023

Study completion Aug 17, 2023

Sponsor

Lead sponsor
Soleno Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.

Conditions

  • Prader-Willi Syndrome

Interventions

  • DCCRDrug

    Once daily oral administration of open-label DCCR tablet(s) during the OLE Period

  • DCCRDrug

    Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period

  • Placebo for DCCRDrug

    Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess the safety of DCCR by evaluating the incidence and severity of adverse events reportedTime frame: Baseline to end of OLE (up to 4 years)
  2. Change from RW Period Baseline in HQ-CT Total ScoreTime frame: RW Period Baseline to Week 16

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Orange, California

  • Stanford University

    Palo Alto, California

  • Rady Children's Hospital San Diego

    San Diego, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Florida Gainesville

    Gainesville, Florida

  • Emory Children's Center

    Atlanta, Georgia

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Kansas University Medical Center

    Kansas City, Kansas

  • National Institutes of Health Hatfield Clinical Research Center

    Bethesda, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Sparrow Clinical Research Institute

    Lansing, Michigan

  • Children's Minnesota

    Saint Paul, Minnesota

  • St. Joseph's University Medical Center

    Paterson, New Jersey

  • NYU Winthrop Hospital

    Mineola, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Research Institute at Nationwide Children's Hospital

    Columbus, Ohio

  • Vanderbilt University

    Nashville, Tennessee

  • Research Institute of Dallas

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • Birmingham Women's and Children's Hospital

    Birmingham, United Kingdom

  • Fulbourn Hospital

    Cambridge, United Kingdom

  • Aintree University Hospital NHS Foundation Trust

    Liverpool, United Kingdom

  • Royal London Hospital

    London, United Kingdom

  • Chelsea and Westminster Hospital

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

  • The Queen Elizabeth University

    Glasgow, Scottland, United Kingdom

  • Hull and East Yorkshire Hospitals NHS Trust

    Hull, Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.